Aligos therapeutics begins dosing with antisense oligonucleotide drug candidate, alg-020572, in healthy volunteers in a phase 1 proof-of-concept study

Aligos now evaluating three of its four chronic hepatitis b (chb) portfolio drug candidates in clinical trials aligos now evaluating three of its four chronic hepatitis b (chb) portfolio drug candidates in clinical trials

ALGS Ratings Summary

ALGS Quant Ranking